Toward a proportionate regulatory framework for gene transfer: A patient group-led initiative

Human Gene Therapy

Volumn 22, Issue 2, 2011, Pages 126-134

  Kent, Alastair ^a   King, Nancy M P ^b   Cohen Haguenauer, Odile ^c,d  

^a GENETIC ALLIANCE UK   (United Kingdom)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELL THERAPY; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); GENE THERAPY; GENE TRANSFER; MEDICAL SOCIETY; PATIENT CARE; PATIENT DECISION MAKING; PATIENT PARTICIPATION; REVIEW;

BIOLOGICAL PRODUCTS; CLINICAL TRIALS AS TOPIC; EUROPEAN UNION; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; LEGISLATION, DRUG; PATIENT ADVOCACY;

EID: 79951842492     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2010.163     Document Type: Review

References (36)

1. Arkin, L.A., Sondhi, D., Worgall, S., et al. (2005). Confronting the issues of therapeutic misconception, enrollment decisions, and personal motives in genetic medicine-based clinical research studies for fatal disorders. Hum. Gene Ther. 16, 1028-1036. (Pubitemid 41324562)
2. Churchill, L.R., Collins, M.L., King, N.M.P., et al. (1998). Genetic research as therapy: implications of "gene therapy" for informed consent. J. Law Med. Ethics 26, 38-47. (Pubitemid 128449388)
3. Commission of the European Communities. (2006a). Directive 2006/17/EC of 8 February 2006 implementing Directive 2004/23/EC as regards certain technical requirements for the donation, procurement and testing of human tissues and cells. Official Journal of the European Union 9/2/2006, L 38/40-L 38/52. Available at http://eur-lex.europa.eu/LexUriServ/site/en/oj/2006/l-038/l- 03820060209en00400052.pdf (accessed January 2011).
4. Commission of the European Communities. (2006b). Directive 2006/86/EC of 24 October 2006 implementing Directive 2004/23/EC as regards traceability requirements, notification of serious adverse reactions and events and certain technical requirements for the coding, processing, preservation, storage and distribution of human tissues and cells. Official Journal of the European Union 25.10.2006, L 294/32-L 294/50. Available at http://eur-lex.europa.eu/LexUriServ/ LexUriServ.do?uri OJ:L:2006:294:0032:0050:EN:PDF (accessed January 2011).
5. European Commission, Enterprise and Industry Directorate General. (2009a). Detailed guidelines on good clinical practice specific to advanced therapy medicinal products. ENTR/F/2/
6. European Commission, Enterprise and Industry Directorate General. (2009b). Assessment of the functioning of the "clinical trials directive" 2001/20/EC: Public consultation paper. ENTR/F/2/SF D(2009) 32674. Available at http://ec .europa.eu/health/files/clinicaltrials/docs/2009- 10-09-public-consultation-paper.pdf (accessed January 2011).
7. European Medicines Agency. (2009a). The EMEA transparency policy EMEA/232037/2009. Available at www.ema.europa .eu/pdfs/human/transparency/ 23203709en.pdf (accessed January 2011).
8. European Medicines Agency. (2009b). Information on benefit-risk of medicines: patients', consumers' and healthcare professionals' expectations. EMEA/40926/2009. Available at www .ema.europa.eu/pdfs/human/pcwp/4092609en.pdf (accessed January 2011).
9. European Medicines Agency. (2009c). ICH considerations: On-colytic viruses. EMEA/CHMP/ICH/607698/2008. Available at www.ema.europa.eu/pdfs/human/ genetherapy/60769808 enfin.pdf (accessed January 2011).
10. European Medicines Agency. (2009d). ICH considerations: General principles to address virus and vector shedding. EMEA/CHMP/ICH/449035/2009. Available at www.ema .europa.eu/pdfs/human/ich/44903509en.pdf (accessed January 2011).
11. European Medicines Agency, Committee for Advanced Therapies. (2010a). Scientific guideline on the minimum quality and non-clinical data for certification of advanced therapy medicinal products. EMEA/CAT/486831/2008 EMA. Available at www.ema.europa.eu/pdfs/human/cat/48683108en.pdf (accessed January 2011).
12. European Medicines Agency, Committee for Advanced Therapies. (2010b). Reflection paper on stem cell-based medicinal products. EMA/CAT/571134/2009. Available at www .ema.europa.eu/pdfs/human/cat/57113409en.pdf (accessed January 2011).
13. European Medicines Agency, Committee for Human Medicinal Products. (2007). Guideline on human cell-based medicinal products. EMEA/CHMP/410869/2006. Available at http://www.ema.europa.eu/docs/en-GB/document-library/Scientific- guideline/2009/09/WC500003898.pdf (accessed January 2011).
14. European Medicines Agency, Committee for Medicinal Products for Human Use. (2005). Guideline on development and manufacture of lentiviral vectors. CPMP/BWP/2458/2003. Available at http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2009/10/WC5000039 84.pdf (accessed January 2011).
15. European Medicines Agency, Committee for Medicinal Products for Human Use. (2006). Guideline on non-clinical testing for inadvertent germline transmission of gene transfer vectors. EMEA/273974/2005. Available at http://www.ema.europa .eu/docs/en-GB/document-library/Scientific-guideline/2009/ 10/WC500003982.pdf (accessed January 2011).
16. European Medicines Agency, Committee for Medicinal Products for Human Use. (2007a). Guideline on the non-clinical studies required before first clinical use of gene therapy medicinal products. EMEA/CHMP/GTWP/125459/2006. Available at http://www.ema.europa.eu/docs/en-GB/document-library/Scientific- guideline/2009/09/WC500003743.pdf (accessed January 2011).
17. European Medicines Agency, Committee for Medicinal Products for Human Use. (2007b). Guideline on scientific requirements
18. for the environmental risk assessment of gene therapy medicinal products. CHMP/GTWP/125491/2006. Available at http://www.ema.europa.eu/docs/en-GB/ document-library/Scientific-guideline/2009/09/WC500003744.pdf (accessed January 2011).
19. European Medicines Agency, Committee for Medicinal Products for Human Use. (2008a). Guideline on follow up of patients administered with gene therapy medicinal products. EMEA/CHMP/GTWP/60436/2007. Available at http://www.ema .europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003954. pdf (accessed January 2011).
20. European Medicines Agency, Committee for Medicinal Products for Human Use. (2008b). Guideline on safety and efficacy follow-up-risk management of advanced therapy medicinal products. EMEA/149995/2008. Available at http://www .ema.europa.eu/pdfs/human/advancedtherapies/14999508 enfin.pdf (accessed January 2011).
21. European Medicines Agency, Committee for Medicinal Products for Human Use. (2009a). Draft concept paper on the development of a guideline on the risk-based approach according to Annex I, Part IV of Dir. 2001/83/EC applied to ATMPs. EMA/CHMP/CPWP/708420/2009. Available at www.ema .europa.eu/pdfs/human/ cpwp/70842009en.pdf (accessed January 2011).
22. European Medicines Agency, Committee for Medicinal Products for Human Use. (2009b). Reflection paper: Quality, non-clinical and clinical issues relating specifically to recombinant adeno-associated viral vectors. EMEA/CHMP/GTWP/587488/2007. Available atwww.ema.europa.eu/pdfs/human/ genetherapy/58748807en.pdf (accessed January 2011).
23. European Medicines Agency, Committee for Medicinal Products for Human Use. (2009c). Questions and answers document on gene therapy. EMA/CHMP/GTWP/212377/2008. Available at www.ema.europa.eu/pdfs/human/ genetherapy/21237708 en.pdf (accessed January 2011).
24. European Medicines Agency, Committee for Medicinal Products for Human Use. (2009d). Concept paper on the revision of the note for guidance on the quality, pre-clinical and clinical aspects of gene transfer medicinal products. EMA/CHMP/GTWP/BWP/234523/2009. Available at www.ema.europa .eu/pdfs/human/ genetherapy/23452309en.pdf (accessed January 2011).
25. European Medicines Agency, Committee for Medicinal Products for Human Use. (2010a). multidisciplinary guidelines introduction. Available at http://www.ema.europa.eu/htms/human/humanguidelines/multidiscipline.htm (accessed January 2011).
26. European Medicines Agency, Committee for Medicinal Products for Human Use. (2010b). Guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells. EMA/CHMP/GTWP/671639/ 2008. Available at www.ema.europa.eu/pdfs/human/genetherapy/67163908 en.pdf (accessed January 2011).
27. Goodyear, M. (2006). Learning from the TGN1412 trial. BMJ 332, 677-678. (Pubitemid 44365678)
28. Henderson, G.E., Easter, M.M., Zimmer, C., et al. (2006). Therapeutic misconception in early phase gene transfer trials. Social Sci. Med. 62, 239-253. (Pubitemid 41728121)
29. Henderson, G.E., Churchill, L.R., Davis, A.M., et al. (2007). Clinical trials and medical care: Defining the therapeutic misconception. PLoS Med. 4, 1735-1738. (Pubitemid 350220527)
30. King, N.M.P. (2000). Defining and describing benefit appropriately in clinical trials. J. Law Med. Ethics 28, 332-343.
31. King, N.M.P., and Cohen-Haguenauer, O. (2008). En route to ethical recommendations for gene transfer clinical trials. Mol. Ther. 16, 432-438. (Pubitemid 351314980)
32. King, N.M.P., Henderson, G.E., Churchill, L.R., et al. (2005). Consent forms and the therapeutic misconception: The example of gene transfer research. IRB 27, 1-8. (Pubitemid 41674175)
33. London, A.J., Kimmelman, J., and Emborg, M.E. (2010). Beyond access vs. protection in trials of innovative therapies. Science 328, 829-830.
34. Office of Biotechnology Activities, National Institutes of Health (2011). Links to GeMCRIS and the NIH Guidance on Informed Consent are available at http://oba.od.nih.gov/rdna/rdna .html (accessed January 24, 2011).
35. Schneider, C.K., Salmikangas, P., Jilma, B.; for the Committee for Advanced Therapies (CAT) and CAT Scientific Secretariat (2010). Challenges with advanced therapy medicinal products and how to meet them. Nat. Rev. Drug Discov. 9, 195-201.
36. U.S. Food and Drug Administration. (2010). Treatment use of an investigational new drug. 21 CFR 312.34. Available at http://edocket.access.gpo. gov/cfr-2003/aprqtr/pdf/21cfr312.34.pdf (accessed January 2011).